Ginger Gregory - Net Worth and Insider Trading

Ginger Gregory Net Worth

The estimated net worth of Ginger Gregory is at least $2 Million dollars as of 2023-03-31. Ginger Gregory is the EVP, Human Resources of Biogen Inc and owns about 5,711 shares of Biogen Inc (BIIB) stock worth over $2 Million. Ginger Gregory is also the Chief Human Resources Officer of Dunkin' Brands Group Inc and owns about 8,500 shares of Dunkin' Brands Group Inc (DNKN) stock worth over $905,080. Details can be seen in Ginger Gregory's Latest Holdings Summary section.

Transaction Summary of Ginger Gregory

To

Ginger Gregory Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ginger Gregory owns 2 companies in total, including Biogen Inc (BIIB) , and Dunkin' Brands Group Inc (DNKN) .

Click here to see the complete history of Ginger Gregory’s form 4 insider trades.

Insider Ownership Summary of Ginger Gregory

Ticker Comapny Transaction Date Type of Owner
BIIB Biogen Inc 2017-07-17 EVP & Human Resources
DNKN Dunkin' Brands Group Inc 2013-04-30 Chief Human Resources Officer

Ginger Gregory Latest Holdings Summary

Ginger Gregory currently owns a total of 2 stocks. Among these stocks, Ginger Gregory owns 5,711 shares of Biogen Inc (BIIB) as of November 14, 2022, with a value of $2 Million and a weighting of 63.45%. Ginger Gregory also owns 8,500 shares of Dunkin' Brands Group Inc (DNKN) as of April 30, 2013, with a value of $905,080 and a weighting of 36.55%.

Latest Holdings of Ginger Gregory

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BIIB Biogen Inc 2022-11-14 5,711 275.13 1,571,267
DNKN Dunkin' Brands Group Inc 2013-04-30 8,500 106.48 905,080

Holding Weightings of Ginger Gregory


Ginger Gregory Form 4 Trading Tracker

According to the SEC Form 4 filings, Ginger Gregory has made a total of 1 transactions in Biogen Inc (BIIB) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Biogen Inc is the sale of 5,610 shares on November 14, 2022, which brought Ginger Gregory around $2 Million.

According to the SEC Form 4 filings, Ginger Gregory has made a total of 0 transactions in Dunkin' Brands Group Inc (DNKN) over the past 5 years. The most-recent trade in Dunkin' Brands Group Inc is the sale of 32,500 shares on April 30, 2013, which brought Ginger Gregory around $1 Million.

Insider Trading History of Ginger Gregory

Ticker
Company
Date
Buy/Sell
Insider Trading Shares
Shares Change
Price
Cost
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
BIIB
Biogen Inc
2022-11-14
Sell
5,610.00
-49.55%
$300.11
$1,683,620.00
5,711.02
$275.13
-8.32%
2022-12-12
DNKN
Dunkin' Brands Group Inc
2013-04-30
Sell
32,500.00
-79.27%
$38.64
$1,255,800.00
8,500.00
$106.48
175.57%
-
Total 2
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ginger Gregory Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Ginger Gregory Ownership Network

Ownership Network List of Ginger Gregory

No Data

Ownership Network Relation of Ginger Gregory


Ginger Gregory Owned Company Details

What does Biogen Inc do?

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Who are the key executives at Biogen Inc?

Ginger Gregory is the EVP & Human Resources of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , director & President and CEO Christopher Viehbacher , and Head of Pharm Ops and Tech Nicole Murphy .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Ginger Gregory made 1 insider transaction in Biogen Inc (BIIB) with a net sale of 5,610. Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 5,532 shares made by Susan H Alexander ,

In summary, during the past 3 months, insiders sold 0 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,142 shares of Biogen Inc (BIIB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,142 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Biogen Inc Insider Transactions

20/Page
Total 0
Ticker
Insider
Position
Date
Buy/Sell
Shares
Shares Owned
Trade Price($)
Trade Percentage(%)
Cost($1000)
Price change since trade(%)
Share ownership details
Filing Date
20/Page
Total 0

Ginger Gregory Mailing Address

Above is the net worth, insider trading, and ownership report for Ginger Gregory. You might contact Ginger Gregory via mailing address: C/o Biogen Inc., 225 Binney St., Cambridge Ma 02142.